TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

14B.4 Checkley AM et al. Eosinophilia in returning travelers and migrants from the tropics: UK recommendations
for investigation and initial management. J Infect 2010;60:1-20.
14B.5 Insiropong S et al. Treatment of eosinophilia with albendazole. Southeast Asian J Trop Med Public
Health 2008;39:517-20.
14B.6 Meltzer E et al. Eosinophilia among returning travelers: a practical approach. Am J Trop Med Hyg
2008;78:702-9.
14B.7 Seybolt LM et al. Diagnostic evaluation of newly arrived asymptomatic refugees with eosinophilia.
Clin Infect Dis 2006;42:363-7.
14B.8 Diaz JH. Recognizing and reducing the risks of helminthic eosinophilic meningitis in travelers: differential
diagnosis, disease management, prevention and control. J Travel Med 2009;16:267-75.
14B.9 Chitkara RK et al. Parasitic pulmonary eosinophilia. Semin Respir Crit Care Med 2006;27:171-84.
14B.10 Lim JM et al. Eosinophilic meningitis caused by Angiostrongylus cantonensis: a case report and literature
review. J Travel Med 2004;11:388-90.
14B.11 Lo Re V et al. Eosinophilic meningitis due to Angiostrongylus cantonensis in a returned traveler: case
report and review of the literature. Clin Infect Dis 2001;33:e112-5.
14B.12 Tsai HC et al. Eosinophilic meningitis caused by Angiostrongylus cantonensis: report of 17 cases.
Am J Med 2001;111:109-114.
14B.13 Slom TJ et al. An outbreak of eosinophilic meningitis caused by Angiostrongylus cantonensis in travelers
returning from the Caribbean. N Engl J Med 2002;346:668-75.
14B.14 Lo Re V et al. Eosinophilic meningitis. Am J Med 2003;114:217-23.
14B.15 Page KR et al. Eosinophilia in a patient from South America. J Am Med Assoc 2008;299:437-44.
14B.16 Lo Re V et al. Eosinophilic meningitis. Am J Med 2003;114:217-23.
15.1 Fradin MS et al. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med
2002;347:13-8.
15.2 Goodyer LI et al. Expert review of the evidence base for arthropod bite avoidance. J Travel Med
2010;17:182-92.
15.3 Schlagenhauf P et al. Malaria chemoprophylaxis: strategies for risk groups. Clin Microbiol Rev
2008;21:466-72.
15.4 Lalloo DG et al. Preventing malaria in travellers. Br Med J 2008;336:1362-6.
15.5 Chen LH et al. Controversies and misconceptions in malaria chemoprophylaxis for travelers. J Am
Med Assoc 2007;297:2251-63.
15.6 Freedman DO. Malaria prevention in short-term travelers. N Engl J Med 2008;359:603-12.
15.7 Schlagenhauf P et al. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan
Africa: multicentre, randomised, double blind, four arm study. Br Med J 2003;327:1078-83.
15.8 Petersen E. Malaria chemoprophylaxis: when should we use it and what are the options? Expert Rev
Anti Infect Ther 2004;2:119-32.
15.9 Shanks GD et al. Modern malaria chemoprophylaxis. Drugs 2005;65:2091-110.
15.10 Chen LH et al. New strategies for the prevention of malaria in travelers. Infect Dis Clin North Am
2005;19:185-210.
15.11 Chen LH et al. Prevention of malaria in long-term travelers. J Am Med Assoc 2006;296:2234-44.
15.12 Chen LH et al. Controversies and misconceptions in malaria chemoprophylaxis for travelers. J Am
Med Assoc 2007;297:2251-63.
15.13 Franco-Paredes C et al. Problem pathogens: prevention of malaria in travellers. Lancet Infect Dis
2006;6:139-49.
15.14 Shetty AK et al. Prevention of malaria in children. Pediatr Infect Dis J 2006;25:1173-6.
15.15 Lalloo DG et al. Malaria in adolescence: burden of disease, consequences, and opportunities for intervention.
Lancet Infect Dis 2006;6:780-93.
15.16 Fischer PR et al. Prevention of malaria in children. Clin Infect Dis 2002;34:493-8.
15.17 McGready R et al. Malaria and the pregnant traveller. Travel Med Infect Dis 2004;2:127-42.
15.18 Menéndez C et al. Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect
Dis 2007;7:126-35.
15.19 Rogerson SJ et al. Treatment and prevention of malaria in pregnancy: opportunities and challenges.
Expert Rev Anti Infect Ther 2006;4:687-702.
15.20 Bertchy S et al. Discontinuation of maintenance therapy against Toxoplasma encephalitis in AIDS patients
with sustained response to anti-retroviral therapy. Clin Microbiol Infect 2006;12:666-71.
15.21 Miro JM et al. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in
HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results
of an open, randomized, multicenter clinical trial. Clin Infect Dis 2006;43:79-89.
15.22 Bertchy S et al. Discontinuation of maintenance therapy against Toxoplasma encephalitis in AIDS patients
with sustained response to anti-retroviral therapy. Clin Microbiol Infect 2006;12:666-71.
15.23 Miro JM et al. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in
HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results
of an open, randomized, multicenter clinical trial. Clin Infect Dis 2006;43:79-89.
15.24 Montoya JG et al. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis
2008;47:554-66.
15.25 Petersen E. Prevention and treatment of congenital toxoplasmosis. Expert Rev Anti Infect Ther
2007;5:285-93.
15.26 The SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group. Effectiveness of prenatal
treatment for congenital toxoplasmosis: a meta-analysis of individual patients‘ data. Lancet
2007;369:115-22.
15.27 Kravetz JD et al. Toxoplasmosis in pregnancy. Am J Med 2005;118:212-6.
15.28 Centers for Disease Control and Prevention (CDC). Preventing congenital toxoplasmosis. Morb Mortal
Wkly Rep 2000;49(RR-2):59-75.
15.29 Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of opportunistic
infections in HIV-infected adults and adolescents. Morb Mortal Wkly Rep 2009;58(RR-4):1-
207.
15.30 Centers for Disease Control and Prevention (CDC). Guidelines for the prevention and treatment of
opportunistic infections among HIV-exposed and HIV-infected children. Morb Mortal Wkly Rep 2009;
58(RR-11):1-167.